RDHL Stock Overview
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
RedHill Biopharma Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.27|
|52 Week High||US$3.37|
|52 Week Low||US$0.25|
|1 Month Change||-59.85%|
|3 Month Change||-69.34%|
|1 Year Change||-89.58%|
|3 Year Change||-95.96%|
|5 Year Change||-94.26%|
|Change since IPO||-97.61%|
Recent News & Updates
|RDHL||US Pharmaceuticals||US Market|
Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.
Return vs Market: RDHL underperformed the US Market which returned -16.1% over the past year.
|RDHL Average Weekly Movement||19.4%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: RDHL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: RDHL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.
RedHill Biopharma Ltd. Fundamentals Summary
|RDHL fundamental statistics|
Is RDHL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RDHL income statement (TTM)|
|Cost of Revenue||US$35.17m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.43|
|Net Profit Margin||-129.88%|
How did RDHL perform over the long term?See historical performance and comparison